icon-folder.gif   Conference Reports for NATAP  
 
  EASL - The International Liver Congress 2014
49th Annual Meeting of the European
Association for the Study of the Liver
London, United Kingdom  April 9-13
Back grey_arrow_rt.gif
 
 
 
An Interferon- and Ribavirin-Free 12-Week Regimen of Once-Daily VX-135 and Daclatasvir in Treatment-Naïve Patients With Genotype 1 HCV Infection
 
 
  Reported by Jules Levin
EASL 2014 April 9-13 London, UK
 
E. Gane1, C. Stedman2, V. Garg3, S. George3, T. Kieffer3, J. Krop3, L. Lan3, R. Rubin3, and A. Lawal3
1. Auckland Clinical Studies, Grafton, New Zealand; 2. Christchurch Clinical Studies, Christchurch, New Zealand; 3. Vertex Pharmaceuticals Incorporated, Boston, MA, USA
 
Vertex Announces Sustained Viral Response Rate (SVR4) Data from All-Oral Study of VX-135 in Combination with Daclatasvir in Hepatitis C - (01/31/14)
 
VX-135, A Once-daily Nucleotide HCV Polymerase Inhibitor, Was Well Tolerated And Demonstrated Potent Antiviral Activity When Given With Ribavirin In Treatment-naïve Patients With Genotype 1
HCV......http://www.natap.org/2013/AASLD/AASLD_14.htm

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif